Physician
Hematology
Dr. Brian L. Samuels, MD
|
|
Give Review
Brian Samuels practices Hematology. He researched medicine at University of Zimbabwe Huggins School of Medicine. He received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Chicago Magazine: Top Doctors". Brian L. Samuels is a published doctor and has 56 publications published. The lastest was: 'Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.' Brian Samuels accepts Medicare.
Publications
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide ex...
- Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results ...
- Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
- Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
- Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation.
- Management of recurrent desmoid tumor after surgery and radiation: role of cytotoxic and non-cytotoxic therapies.
- Scrotal thermography.
- Lesion detectability in ultrasonic computed tomography of symptomatic Breast patients.
- Modulation of vinblastine resistance with cyclosporine: a phase I study.
- Allogeneic hematopoietic transplantation for mantle-Cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
- Irinotecan in relapsed or refractory non-Hodgkin's Lymphoma.
- Lovastatin effects on human breast carcinoma Cells. Differential toxicity of an adriamycin-resistant derivative and influence on selenocysteine tRNAS.
- Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast Cancer.
- Decreased insulin binding in cultured lymphocytes from two patients with extreme insulin resistance.
- Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy.
- Brachial plexopathy after intraarterial cisplatin.
- Continuous venous infusion of doxorubicin in advanced sarcomas.
- Infusional vinorelbine in relapsed or refractory Lymphomas.
- Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant Lymphoma.
- Dedifferentiated Chordoma. Response to aggressive chemotherapy in two cases.
- Heat shock proteins in normal and leukemic blood Cells.
- Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
- A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant Lymphoma.
- Increased glutathione peroxidase activity in a human sarcoma Cell line with inherent doxorubicin resistance.
- Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results.
- Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
- Liposomal vincristine in relapsed non-Hodgkin''s Lymphomas: early results of an ongoing phase II trial.
- Trimetrexate in relapsed T-Cell lymphoma with skin involvement.
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-Cell transplantation: an active regimen for aggressive mantle-Cell lymphoma.
- High-dose intravenous melphalan: a review.
- Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for Rectal carcinoma: a phase II study with long-term follow-up.
- Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and Leukemia group B study.
- Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast Cancer (>10 involved lymph nodes) treated with high...
- A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast Cancer.
- Ifosfamide plus paclitaxel in advanced non-small-cell lung Cancer: a phase I study.
- Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung Cancer.
- Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung Cancer.
- A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung Cancer: rationale and study design.
- Ifosfamide-based combination chemotherapy in advanced non-small cell lung Cancer: two phase I studies.
- Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck Cancer.
- Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary Carcinoma.
- Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung Cancer.
- A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung Cancer.
- Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatoCellular carcinoma.
- A review of ifosfamide and vinorelbine in advanced non-small Cell carcinoma of the lung.
- Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast Cancer.
- Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
- A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung Cancer.
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance fo...
- Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
- Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung Cancer.
- Androgen and c-Kit receptors in desmoplastic small round Cell tumors resistant to chemotherapy: novel targets for therapy.
- A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.
- A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast Cancer.
- Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Schools
Godfrey Huggins School Of Medicine
Harare Hospital University Of Rhodesia
Albert Einstein Med Center
Johannesburg Hospital University Witwate
University of Chicago
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Chicago Magazine: Top Doctors
Education
-
University of Chicago -
Albert Einstein Healthcare Network -
University of Zimbabwe Huggins School of Medicine
Drug Facts
| NPI NUMBER | 1396776027 | |
| NPPES Provider LastName | SAMUELS | |
| NPPES Provider FirstName | BRIAN | |
| NPPES Provider ZIPCode | 838142656 | |
| NPPES Provider State | ID | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 840.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 109.0 | |
| Percent Opioid Claims | 12.98 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396776027 |
| Last Name Of The Provider | SAMUELS |
| First Name Of The Provider | BRIAN |
| View All |
Similar Doctors
|
|
Dr. Judith M. Lyding, MD |
|
|
Dr. Haluk Tezcan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naseer Ahmad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberly A. Morley, MD
This Doctor is OpenDoctor Recommended.
|